TWiV is a weekly netcast about viruses - the kind that make you sick. Brought to you by four university professors and a science writer.
http://www.microbe.tv/twiv
Gesamtlänge aller Episoden: 55 days 13 hours 23 minutes
episode 838: The magic virus bus
The New York City Virus Hunters join TWiV to reveal how local students engage in safe virus surveillance and conduct science research right in their neighborhoods, followed by an update on variant of concern Omicron.
episode 837: COVID-19 clinical update #91 with Dr. Daniel Griffin
In COVID-19 clinical update #91, Dr. Griffin discusses final results of molnupiravir trial, Omicron variant of concern, outcomes in B-cell depleted patients, recovery in T-cell depleted macaques, peptide for induction of T cell immunity, high...
episode 836: OMG, Omicron!
TWiV reveals all that we know so far about the variant of concern B.1.1.529, also called Omicron, and describes a study on the ability of the alpha, beta, and delta variants to reproduce in cells in culture and induce membrane fusion.
episode 835: Giving thanks for antibodies
TWiV reviews why children should be vaccinated against COVID-19, increased risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variant compared to Alpha variant in vaccinated but not recovered individuals, and immune correlates of protection from...
episode 834: COVID-19 clinical update #90 with Dr. Daniel Griffin
In COVID-19 clinical update #90, Dr. Griffin covers FDA expansion for booster doses, 3 more at home antigen tests approved by FDA, immune correlates analysis of mRNA-1273 vaccine, risk for stillbirth, PROVENT prophylaxis trial results, fluvoxamine...
episode 833: Grand theft kinesin
TWiV reviews Michael Worobey’s dissection of the early COVID-19 cases in Wuhan, and the discovery that herpesviruses assimilate cellular kinesin to produce motorized virus particles.
episode 832: Heavy metal flu fighters
TWiV reviews the vials labeled smallpox that were not, re-emergence of enterovirus D68 in Europe, efficacy of inactivated SARS-CoV-2 vaccine, and cellular correlates of protection for an oral influenza virus vaccine.
episode 831: COVID-19 clinical update #89 with Dr. Daniel Griffin
In COVID-19 clinical update #89, Dr. Griffin reviews upcoming meeting on FDA emergency use authorization for molnupiravir, 25% of US cases in children, reinfection associates with presence of antibodies, national surveillance for acute flaccid...
episode 830: A culture of resistance
TWiV explains that a recent report suggesting that the SARS-CoV-2 spike protein inhibits V(D)J recombination in vitro would not impact immunity after infection or vaccination, and describes the isolation of remdesivir resistant mutants in cells in...
episode 829: Antiviral and cytotoxically empowered for COVID-19
A TWiV duo reviews how SARS-CoV-2 attacks the olfactory mucosa but spares the olfactory bulb, vaccination with BNT162b2 induces virus-specific stem cell memory T cells, and development of an oral protease inhibitor for the treatment of COVID-19.